Show simple item record

dc.contributor.authorHollis, Chris P.
dc.date.accessioned2018-11-30T11:25:17Z
dc.date.available2018-11-30T11:25:17Z
dc.date.issued2018
dc.identifier.citationCipriani, A., Adamo, N., Giovane, C. D., Coghill, D., Banaschewski, T., Hollis, C. P., Zuddas, A., Simonoff, E. & Cortese, S. (2018). Unbalanced risk-benefit analysis of ADHD drugs - Authors' reply. The Lancet Psychiatry, 5 (11), pp.871-873.en
dc.identifier.other10.1016/S2215-0366(18)30396-1
dc.identifier.urihttp://hdl.handle.net/20.500.12904/7707
dc.description.urihttps://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(18)30396-1/fulltext#%20en
dc.subjectRisk assessmenten
dc.subjectAttention deficit disorder with hyperactivityen
dc.subjectDrug therapyen
dc.titleUnbalanced risk-benefit analysis of ADHD drugs - Authors' replyen
dc.typeCorrespondence


This item appears in the following Collection(s)

Show simple item record